FTSE 100 extends gains on Pfizer’s Covid-19 vaccine hopes
The blue-chip index continues to soar this week on hopes of a potential breakthrough in the search for a vaccine against Covid-19 after Pfizer drug trial reveals 90% effective rate.
- FTSE 100 up 6% over last two sessions this week on Covid-19 vaccine hopes
- Pfizer coronavirus vaccine 90% effective
- Blue-chip index rally could peter out if vaccine trials are unable to clear all hurdles
The FTSE 100 extended its gains on Tuesday, with investors hopeful of a potential breakthrough in the search for a vaccine against Covid-19.
The blue-chip index built on its strong performance last week, with the index buoyed by Joe Biden winning the US presidential election, bringing an end to Donald Trump’s controversial time in the White House.
The FTSE 100 is up more than 11% over the last seven trading sessions, closing at 6296 points on Tuesday, with the index down 17% year-to-date.
Pfizer’s Covid-19 vaccine 90% effective
The US-based drug maker, Pfizer, saw its share price soar 15% on Monday after it announced that its coronavirus vaccine was 90% effective, according to its preliminary analysis.
The new drug, which has been developed by Pfizer and BioNTech, has been tested on 43,500 people across six countries with no safety concerns raise, with the two companies seeking emergency approval to start using the vaccine by the end of November.
It is worth noting that the vaccine still has a number of hurdles that it must clear before it can be rolled out, but overall the announcement has been met warmly by scientists worldwide, with some believing life could return to normal as early as spring.
‘Today is a great day for science and humanity,’ Pfizer Chairman and CEO Dr Albert Bourla said. ‘The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.’
‘We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,’ he added.
‘With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.’
Pfizer is trading at $38.80 per share at the time of publication, with the stock down 0.84% year-to-date.
FTSE 100: technical analysis
The FTSE 100 saw massive gains yesterday as traders jumped into value stocks over the big tech names, according to Josh Mahony, senior market analyst at IG.
‘That rise looks like it could continue, with the index attempting to push higher from here. A break through the 6462 peak from yesterday would provide a fresh near-term bullish signal for the index,’ he said.
‘Conversely, a decline below the 6103 level would bring about questions over the potential for a retracement phase coming into play,’ Mahony added.
‘However, whether that pullback comes into play or not, the break through 6038 does appear to have marked an end to the downtrend that has been in place since the June peak.’
FTSE 100: after-hours trading with IG
IG offers extended hours trading options for the FTSE 100 index and other major indices. Buy long or sell short on the FTSE 100 via CFDs and spread bets provided by IG's market-leading trading solution. Start by opening a live or demo account with IG today.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Seize your opportunity
Deal on the world’s stock indices today.
- Trade on rising or falling markets
- Get one-point spreads on the FTSE 100
- Unrivalled 24-hour pricing
See opportunity on an index?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on an index?
Don’t miss your chance – upgrade to a live account to take advantage.
- Get spreads from one point on the FTSE 100
- Trade more 24-hour indices than any other provider
- Analyse and deal seamlessly on smart, fast charts
See opportunity on an index?
Don’t miss your chance. Log in to take your position.
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.